ProCE Banner Activity

Phase I Results of Ongoing Trial Assessing Mesothelin-Targeted CAR T-Cell Therapy ± Pembrolizumab in Malignant Pleural Cancers

Slideset Download
Conference Coverage
Early data suggest that mesothelin-targeted CAR T-cell therapy with or without pembrolizumab is associated with a tolerable safety profile and clinical activity in patients with malignant pleural cancers.

Share

Provided by

Provided by Clinical Care Options, LLC.
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Bayer Healthcare Pharma

Daiichi Sankyo, Inc.

Janssen administered by Scientific Affairs

Janssen Pharmaceutica NV

Millennium Pharmaceuticals Inc Subsidary of Takeda

Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme